# eGenesis

> eGenesis is a Cambridge, Massachusetts clinical-stage biotechnology company using multiplex CRISPR gene editing to engineer pig organs that the human body will accept. Its EGEN platform makes dozens of edits to a porcine genome at once - removing pig antigens, adding human genes, and inactivating embedded retroviruses - to create kidneys, livers, and hearts intended to ease the global organ shortage. In 2024 its lead candidate became the basis of the world's first gene-edited pig kidney transplant in a living patient, and in 2025 the FDA cleared it for a formal clinical trial.

- **Founded:** 2015
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** George Church (Co-Founder (Harvard/Wyss geneticist)), Luhan Yang (Co-Founder, former Chief Scientific Officer)
- **Team size:** ~150 employees
- **Products:** EGEN Platform, EGEN-2784, EGEN-5784, Pediatric heart program
- **Notable:** Enabled the world's first transplant of a genetically engineered pig kidney into a living human patient (March 2024, Mass General, FDA Expanded Access)., Received FDA IND clearance in 2025 for EGEN-2784, the first broad clinical trial of a gene-edited pig kidney for end-stage kidney disease., Produced the world's longest-living recipient of a gene-edited porcine organ (patient Tim Andrews, surpassing seven months post-transplant).

## Products & services

- **EGEN Platform** — Proprietary Genome Engineering and Production platform that applies multiplex CRISPR editing to porcine cells - removing pig carbohydrate antigens, inserting human transgenes, and inactivating porcine endogenous retroviruses - then producing cloned, biosecure donor animals.
- **EGEN-2784** — Lead candidate: a genetically engineered porcine kidney for patients with end-stage kidney disease. Used in the world's first living pig-kidney transplant (2024) and FDA-cleared for a Phase 1/2/3 clinical trial in 2025.
- **EGEN-5784** — Engineered porcine liver program for acute liver failure, developed with OrganOx's extracorporeal cross-circulation system to support patients while their own liver recovers.
- **Pediatric heart program** — Engineered porcine heart program aimed at pediatric heart failure, an area with especially scarce donor supply.

## Achievements

- Enabled the world's first transplant of a genetically engineered pig kidney into a living human patient (March 2024, Mass General, FDA Expanded Access).
- Received FDA IND clearance in 2025 for EGEN-2784, the first broad clinical trial of a gene-edited pig kidney for end-stage kidney disease.
- Produced the world's longest-living recipient of a gene-edited porcine organ (patient Tim Andrews, surpassing seven months post-transplant).
- Pioneered inactivation of porcine endogenous retroviruses (PERVs) across the genome, addressing a decades-old viral-safety barrier to xenotransplantation.
- Raised roughly $481M across four rounds from leading life-science investors.
- Named to Fast Company's Most Innovative Companies of 2026.

## Latest updates

- **2025-06** — Bill Stewart, 54, became the third patient overall to receive an EGEN-2784 porcine kidney (June 14, 2025).
- **2025** — FDA cleared the IND for EGEN-2784, authorizing a Phase 1/2/3 trial in dialysis-dependent ESKD patients age 50+; longest-living recipient passed seven months post-transplant.
- **2025-01** — Tim Andrews, 67, received an EGEN-2784 kidney at Mass General (Jan 25, 2025) and became the longest-surviving recipient of a gene-edited pig organ.
- **2024-09** — Closed $191M Series D led by Lux Capital to advance the kidney program to a first-in-human study and scale production.
- **2024-03** — Lead kidney candidate used in the world's first porcine kidney transplant in a living patient under FDA Expanded Access.

## Links

- Website: https://egenesisbio.com
- LinkedIn: https://www.linkedin.com/company/egenesisbio
- Twitter/X: https://twitter.com/eGenesisBio
- Facebook: https://facebook.com/eGenesisBio/

---

Profile page: https://yespress.io/egenesis
Published by YesPress — https://yespress.io
Last updated: 2026-06-15